검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BV (Induction with Brentuximab vedotin, Induction with Brentuximab vedotin (BV)) Seagen / Takeda·Hodgkin Lymphoma, Adult ORR 78.3% |
|---|---|
Overview Program | Induction with Brentuximab vedotin (BV) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma, Adult |
Overview Indication | Hodgkin Lymphoma, Adult |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting the Urotensin II Receptor Pathway |
MoA Biomarker | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | The Protective Effects of Small-Molecule Compound 0242 Against LPS-Induced Neuroinflammation and in P301S Tau Transgenic Mice.. Neuroinflammation and tau pathology are central drivers of Alzheimer's disease (AD) progression, necessitating multi-target therapeutic strategies. Here, we evaluated the efficacy and mechanisms of 0242, a novel small-molecule derivative optimized from the berberine scaff… |
Clinical Primary efficacy | ORR 78.3% |
Clinical ORR | 78.3% |
Clinical PFS | 16.5 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT02453594 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BV (Induction with Brentuximab vedotin, Induction with Brentuximab vedotin (BV)) Seagen / Takeda·Hodgkin Lymphoma, Adult ORR 78.3% |
|---|---|
Overview Program | Induction with Brentuximab vedotin (BV) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma, Adult |
Overview Indication | Hodgkin Lymphoma, Adult |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting the Urotensin II Receptor Pathway |
MoA Biomarker | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | The Protective Effects of Small-Molecule Compound 0242 Against LPS-Induced Neuroinflammation and in P301S Tau Transgenic Mice.. Neuroinflammation and tau pathology are central drivers of Alzheimer's disease (AD) progression, necessitating multi-target therapeutic strategies. Here, we evaluated the efficacy and mechanisms of 0242, a novel small-molecule derivative optimized from the berberine scaff… |
Clinical Primary efficacy | ORR 78.3% |
Clinical ORR | 78.3% |
Clinical PFS | 16.5 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT02453594 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교